SCHEMBL22368

SCHEMBL22368

COC1(OC)C=CC(C(Cl)(c2ccccc2)c2ccccc2)=CC1

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL27870524 0.96
SCHEMBL17961618 0.92 KIF11 (0.36)
SCHEMBL28304175 0.87 CHRM2 (0.31)
SCHEMBL5663554 0.83 CHRM2 (0.31)
SCHEMBL8135345 0.83 CHRM3 (0.35)
SCHEMBL28832854 0.82
SCHEMBL28576238 0.78 TSHR (0.33) TSHR
SCHEMBL5185260 0.73
Phenol SCHEMBL28164302 0.68 PDE4A (0.33)
Acetonitrile SCHEMBL28641911 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150390-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-05-09 US claimed
EP-4286393-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE Daiichi Sankyo Company, Limited (JP) 2023-12-06 EP claimed
WO-2022163846-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE 第一三共株式会社 2022-08-04 WO claimed
CN-105381844-B The tooth-like material-pulverizing device of one kind rotation 徐州工程学院 2017-10-27 CN claimed
CN-105399263-B The complete set of equipments and its minimizing technology of ferromanganese ion are removed in a kind of mine water 徐州市城区水资源管理处 2017-08-15 CN claimed
CN-105399263-A Complete equipment for removing iron ions and manganese ions from pit water and removal method thereof XUZHOU CITY URBAN WATER RESOURCE MAN OFFICE 2016-03-16 CN claimed
CN-105381844-A Rotary tooth type material crushing device XUZHOU INST TECHNOLOGY 2016-03-09 CN claimed
CN-105368432-A Pour point depressant for crude oil, preparation method for pour point depressant and application of pour point depressant XUZHOU INST TECHNOLOGY 2016-03-02 CN claimed
US-20120070825-A1 Novel Compounds and Derivatizations of DNAs and RNAs on the Nucleobases of Pyrimidines for Function, Structure and Therapeutics SENA RESEARCH, INC. (US) 2012-03-22 US claimed
WO-2010135564-A2 NOVEL COMPOUNDS AND DERIVATIZATION OF DNAS AND RNAS ON THE NUCLEOBASES OF PYRIMIDINES FOR FUNCTION, STRUCTURE, AND THERAPEUTICS SENA RESEARCH, INC. (US) 2010-11-25 WO claimed
JP-2003520042-A 2003-07-02 JP claimed
EP-1250157-A1 ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2002-10-23 EP claimed
WO-2001052902-A1 ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2001-07-26 WO claimed
CN-122028913-A Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions 阿达尔克斯制药有限公司 2026-05-12 CN disclosed
EP-4707393-A1 DOUBLE-STRANDED SIRNA, CONJUGATE THEREOF AND USE THEREOF CMS Research & Development Pte. Ltd. (SG) 2026-03-11 EP disclosed
EP-4678646-A1 NUCLEOSIDE ANALOG FOR 5'-PHOSPHONATE MODIFICATION AND OLIGONUCLEOTIDE PREPARED THEREFROM Shanghai Argo Biopharmaceutical Co., Ltd. (CN) 2026-01-14 EP disclosed
EP-0333832-B1 ARTIFICIAL DNA BASE PAIR ANALOGUES TEMPLE UNIVERSITY (US) 1992-06-03 EP disclosed
EP-0194545-B1 LABELLING OF OLIGONUCLEOTIDES MOLECULAR DIAGNOSTICS, INC. (US) 1989-12-06 EP disclosed
US-4808520-A HYBRIDIZING WITH NUCLEIC ACID, THEN WITH NUCLEOSIDE TRIPHOSPHATE IN PRESENCE OF ENZYME MOLECULAR DIAGNOSTICS, INC. (US) 1989-02-28 US disclosed
EP-0194545-A2 Labelling of oligonucleotides MOLECULAR DIAGNOSTICS, INC. (US) 1986-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150390-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE PAICS, COASY, CDS2 TSHR 2895/4885
US-20120070825-A1 Novel Compounds and Derivatizations of DNAs and RNAs on the Nucleobases of Pyrimidines for Function, Structure and Therapeutics NSUN2, RNMT, TRDMT1 TSHR 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.